A Triple Combination HIV Microbicide

Description:

Abstract:

The HIV-positive population continues to rise despite a worldwide decline in the rates of infection caused by human immunodeficiency virus (HIV).  The HIV virus continues to spread due to a lack of effective vaccines and pre-exposure prophylaxis methods, even though the availability and effectiveness of antiretroviral therapy has helped reduce acquired immunodeficiency syndrome (AIDS)-related deaths. 

Researchers at the National Cancer Institute (NCI), in collaboration with researchers at the University of Lleida, developed a triple combination microbicide for the prevention of HIV and other sexually transmitted diseases. The microbicide is comprised of an endosperm, the anti-HIV monoclonal antibody 2G12, and the antiviral lectins griffithsin and cyanovirin. The researchers have generated the microbicide combination in transgenic plants as an efficient and cost-effective production method. 

Competitive Advantages:

  • Low cost, stable production method
  • Stable and long-term storage compatible rice seed

Commercial Applications:

  • Effective anti-HIV microbicide with activity against other viruses as well (HSV, HCV)
Patent Information:
For Information, Contact:
Taryn Dick
Technology Transfer Manager
NIH Technology Transfer
301-631-3007
taryn.dick@nih.gov
Inventors:
Barry O'Keefe
Paul Christou
Evangelia Vavamka
Theresa Capell
Keywords:
Acquired Immunodeficiency Syndrome
ANTIBODY
ANTIVIRAL
HIV
Lectin
Microbicide
O’Keefe
Sexually Transmitted Diseases
© 2024. All Rights Reserved. Powered by Inteum